Pharmaceutical company, Mayne Pharma Group Limited (ASX:MYX), has started to promote two dermatology products in the United States, under its specialty franchise brand, Doryx.
The company says both products are in attractive and growing markets. The foam products, namely Fabior is used to treat acne while Sorilux is used to manage psoriasis.
Both products were acquired by Mayne Pharma from GlaxoSmithKline in August 2016.
Mayne Pharma says it also internalised the company’s dermatology sales team which it expects to provide cost savings and improve performance management.
Mayne Pharma posted a net profit of $34.5 million at 30 June 2016.